Evidence-Based · Doctor-Reviewed · No Grey Market BS
Get the Weekly Brief
weight-loss

AOD-9604 Peptide: Complete Guide

AOD-9604 peptide guide for 2026 — fat loss benefits, clinical dosage protocols, side effects, trial data, and current regulatory status you need to know.

By Pure Peptide Clinic Editorial Team · Reviewed by Dr. Javed Iqbal, MBBS · Updated 2026-03-11

AOD-9604 is a modified fragment of human growth hormone (hGH), specifically amino acids 176–191 of the GH molecule with an added tyrosine at the N-terminus. It was developed to isolate the fat-burning properties of growth hormone without the blood sugar disruption, muscle growth, or IGF-1 elevation that come with full GH therapy [1].

Originally developed by Metabolic Pharmaceuticals in Australia during the early 2000s, AOD-9604 went through multiple clinical trials before development stalled. It’s now experiencing renewed interest in the peptide therapy space as a targeted fat loss compound — though its story is more complicated than many marketing claims suggest.

Key Takeaways

  • AOD-9604 is a modified fragment of growth hormone that targets fat metabolism without raising IGF-1 or blood sugar
  • Early clinical trials showed modest fat loss (2.6 kg over 12 weeks at 1 mg/day), but a larger Phase 2b trial failed to reach statistical significance
  • Safety profile is strong — over 900 participants across six trials with minimal adverse effects reported
  • FDA has not approved AOD-9604 and has proposed excluding it from the compounding bulk drug substances list

Table of Contents

What Is AOD-9604?

To understand AOD-9604, you need to understand the problem it was designed to solve.

Human growth hormone does a lot of things: it builds muscle, stimulates bone growth, mobilizes fat stores, and influences blood sugar regulation. For obesity treatment, the fat-burning effects are attractive. But full GH therapy comes with insulin resistance, potential tumor growth stimulation via IGF-1, and significant cost [2].

Australian researchers at Monash University identified that a small fragment of the GH molecule — the C-terminal region spanning amino acids 176 to 191 — appeared responsible for GH’s fat-mobilizing activity. They synthesized this fragment with a stabilizing tyrosine residue and called it AOD-9604 (Anti-Obesity Drug, project number 9604) [1].

The result was a peptide that could stimulate lipolysis (fat breakdown) and inhibit lipogenesis (fat creation) without the diabetogenic effects of full growth hormone. It doesn’t raise IGF-1 levels, doesn’t affect blood sugar, and doesn’t stimulate muscle or bone growth [1][3]. For a broader look at this category, see our guide on peptides for weight loss.

How AOD-9604 Works

AOD-9604 mimics the way natural growth hormone regulates fat metabolism, but through a distinct receptor interaction:

Lipolysis Stimulation. AOD-9604 increases the release of stored fat (triglycerides) from adipose tissue by enhancing beta-3 adrenergic receptor activity. This is the same pathway your body uses during exercise and fasting to mobilize fat stores [1].

Lipogenesis Inhibition. Beyond releasing stored fat, AOD-9604 also reduces the rate at which new fat is created and stored. This dual action — breaking down existing fat while preventing new fat accumulation — is what made it attractive for obesity research [1][3].

No IGF-1 Elevation. Unlike full-length growth hormone, AOD-9604 does not activate the GH receptor in a way that triggers IGF-1 production. This is a meaningful distinction because elevated IGF-1 is associated with insulin resistance and theoretical cancer risk concerns. AOD-9604 sidesteps both [1][4].

Potential Cartilage Effects. More recent research has explored AOD-9604’s effects on cartilage regeneration. Preclinical data suggests it may stimulate proteoglycan and collagen synthesis in chondrocytes, leading to interest in joint health applications beyond its original fat loss purpose [5].

Clinical Trial Evidence

AOD-9604 has more human clinical data than many peptides — but the results tell a mixed story.

Early Trials (Positive Results)

A 12-week randomized, placebo-controlled trial tested oral AOD-9604 at doses of 1 mg/day, 5 mg/day, and 10 mg/day in obese subjects. The 1 mg/day group lost an average of 2.6 kg (about 5.7 lbs) compared to placebo. Higher doses did not produce additional weight loss, suggesting an inverted dose-response curve [2][3].

The safety data from this trial was clean. No significant changes in blood glucose, insulin, IGF-1, cortisol, or thyroid hormones were observed. Side effect profiles were comparable to placebo.

Phase 2b Trial (Failed Primary Endpoint)

The larger Phase 2b trial enrolled 536 obese subjects over 24 weeks. Despite the promising earlier data, AOD-9604 did not produce statistically significant weight loss compared to placebo in this trial [2][6].

This was the trial that effectively ended pharmaceutical development. Metabolic Pharmaceuticals ceased development of AOD-9604 as an obesity drug in 2007 after these disappointing results.

Safety Database

Across all clinical trials — six controlled studies involving over 900 participants — AOD-9604 demonstrated a strong safety profile. No serious adverse events were attributed to the peptide, and metabolic parameters remained stable throughout treatment [3][5].

What This Means

The clinical picture of AOD-9604 is honest but nuanced. It has clear biological activity on fat metabolism. Early trials showed meaningful fat loss. But when tested at scale with the rigor required for drug approval, it didn’t meet the bar. This doesn’t mean it’s ineffective — it means the effect size at the tested oral doses wasn’t large enough for FDA approval as a standalone obesity drug.

Many clinicians now use injectable AOD-9604 at different doses, which may produce different bioavailability and results than the oral formulations used in the failed trial. However, this remains largely supported by clinical observation rather than controlled trial data.

Benefits of AOD-9604

Fat Loss

The primary use case. AOD-9604 targets fat metabolism directly through lipolysis stimulation and lipogenesis inhibition. Clinical evidence supports modest fat reduction, particularly in abdominal adipose tissue [2][3]. It works through a different mechanism than GLP-1 agonists like semaglutide, which reduce appetite through gut hormone signaling.

For those comparing options, our peptides for fat loss guide covers the full picture.

No Metabolic Side Effects

Unlike full growth hormone therapy, AOD-9604 doesn’t affect blood sugar, insulin sensitivity, or IGF-1 levels. This makes it an option for people who want fat-targeted effects without the metabolic risks of GH [1][4]. It won’t cause the joint pain, water retention, or blood sugar issues associated with growth hormone.

Joint and Cartilage Support

Emerging preclinical data suggests AOD-9604 may support cartilage repair by stimulating chondrocyte activity. Some clinicians use it for osteoarthritis and joint issues, though human trial data for this application is limited [5]. For more on peptides and joint health, see peptides for joint pain.

Favorable Safety Profile

With over 900 clinical trial participants and no serious adverse events, AOD-9604 has one of the larger human safety databases among therapeutic peptides. This is a genuine advantage in a space where many peptides rely on animal data alone [3][5].

AOD-9604 Dosage and Protocols

Injectable Protocols

Most current clinical use involves subcutaneous injection rather than the oral dosing used in the original trials. Injectable administration provides higher bioavailability and may explain why practitioners report better results than the oral trials suggested.

ProtocolDosageFrequencyDuration
Standard fat loss300 mcgDaily (subcutaneous)12–16 weeks
Moderate250 mcgDaily12 weeks
Combined (with exercise)300 mcgDaily, morning on empty stomach8–12 weeks

AOD-9604 is typically injected in the morning on an empty stomach, often in abdominal subcutaneous fat near the target area. While “spot reduction” through local injection is debated, the timing aligns with natural fasted fat-burning windows.

For injection guidance, see our how to inject peptides and peptide injection sites guides. Vials require reconstitution with bacteriostatic water before use.

Stacking

AOD-9604 is commonly stacked with other peptides for enhanced fat loss:

  • AOD-9604 + CJC-1295/Ipamorelin — Adds growth hormone secretion for broader body composition effects. See CJC-1295 + Ipamorelin.
  • AOD-9604 + MOTS-C — Combines GH-fragment fat metabolism with mitochondrial AMPK activation for dual-pathway fat loss. See MOTS-C.
  • AOD-9604 + BPC-157 — For those addressing both fat loss and tissue repair simultaneously. See BPC-157.

For structured combination approaches, check our best peptide stack for fat loss guide.

Cycling

Most practitioners recommend cycling AOD-9604 — typically 12 weeks on, 4 weeks off — to prevent receptor desensitization. Some use it continuously at lower maintenance doses. Your prescribing clinician can help determine the right approach as part of a broader peptide protocol.

Side Effects and Safety

AOD-9604’s safety profile is one of its strongest selling points. Across clinical trials [3][5]:

Reported side effects (generally mild):

  • Injection site reactions (redness, mild irritation)
  • Occasional headache
  • Mild nausea, usually transient
  • Temporary flu-like symptoms in first few days

What the trials showed no effect on:

  • Blood glucose and insulin levels
  • IGF-1 or growth hormone levels
  • Cortisol or thyroid hormones
  • Liver or kidney function markers
  • Blood pressure or heart rate

What we don’t know: Long-term safety data beyond 24 weeks is limited. The injectable route now commonly used was not the primary route tested in clinical trials. And as with any peptide from compounding sources, purity and quality matter. For more on safety considerations, see are peptides safe and peptide side effects.

AOD-9604 vs Other Weight Loss Peptides

AOD-9604 vs Semaglutide/Tirzepatide. GLP-1 agonists like semaglutide and tirzepatide produce dramatically more weight loss (15–20%+ of body weight in trials) by suppressing appetite. AOD-9604 works on fat metabolism directly without appetite suppression. They target entirely different mechanisms.

AOD-9604 vs Tesamorelin. Tesamorelin is an FDA-approved growth hormone-releasing hormone analog that reduces visceral fat. Unlike AOD-9604, it raises IGF-1 levels. Tesamorelin has stronger clinical evidence but a narrower approved indication (HIV-associated lipodystrophy).

AOD-9604 vs MOTS-C. MOTS-C works through mitochondrial AMPK activation. AOD-9604 works through GH-fragment fat metabolism. Different mechanisms, sometimes stacked together.

AOD-9604 vs CJC-1295/Ipamorelin. CJC-1295/Ipamorelin stimulates your body’s own GH production, which affects fat loss, muscle, sleep, and recovery. AOD-9604 only targets fat metabolism. The trade-off: CJC/Ipamorelin raises IGF-1, AOD-9604 doesn’t.

For a complete comparison, see our list of peptides and peptides for weight loss guides.

AOD-9604 is not FDA-approved for any medical indication. Its regulatory path has been complicated:

FDA’s Position. The FDA has proposed not including AOD-9604 on the list of bulk drug substances that can be used by compounding pharmacies. The agency cited concerns about immunogenicity risk and insufficient safety data for compounded formulations [7]. This was reviewed at the Pharmacy Compounding Advisory Committee (PCAC) meeting in December 2024.

WADA Status. AOD-9604 is banned by the World Anti-Doping Agency (WADA) under the category of growth hormone releasing factors and fragments. Athletes subject to drug testing cannot use it.

Current Availability. Despite the FDA’s proposed position, AOD-9604 remains available through some compounding pharmacies and research suppliers as of early 2026. The regulatory picture continues to evolve — see our guide on the FDA peptide reclassification for the latest developments.

GRAS Status. Interestingly, AOD-9604 received Generally Recognized as Safe (GRAS) status as a food ingredient in 2014, based on its safety and metabolism data [3]. This applies to oral supplement forms only, not injectable preparations.

For guidance on obtaining AOD-9604 through legitimate medical channels, see how to get peptides prescribed and peptide therapy online.

Explore the evidence: See all 5 AOD-9604 studies in our research database, or browse the full peptide therapy statistics for 2026.

FAQ

Does AOD-9604 actually work for weight loss?▼

The evidence is mixed. A 12-week clinical trial showed 2.6 kg of fat loss at 1 mg/day oral dosing. But a larger 24-week trial failed to show statistically significant weight loss. Many clinicians report positive results with injectable protocols at different doses, but this hasn’t been validated in controlled trials. It’s honest to say it has biological activity on fat metabolism, but the effect size may be modest compared to newer weight loss drugs.

How quickly does AOD-9604 work?▼

Most practitioners report patients noticing changes in body composition within 4–8 weeks of consistent daily use, particularly when combined with exercise and dietary management. Fat loss with AOD-9604 tends to be gradual rather than dramatic.

Can AOD-9604 be taken orally?▼

Yes — the original clinical trials used oral dosing, and it has GRAS status as a food ingredient. However, oral bioavailability is low compared to injection. Most current clinical protocols use subcutaneous injection for better absorption and effect.

Does AOD-9604 affect muscle growth?▼

No. AOD-9604 is specifically the fat-metabolizing fragment of growth hormone. It does not activate the pathways responsible for muscle growth or IGF-1 production. If muscle building is a goal, look at peptides for muscle growth like CJC-1295/Ipamorelin or similar GH secretagogues.

Is AOD-9604 safe with diabetes medications?▼

Clinical trials showed no effect on blood glucose or insulin levels, which is theoretically favorable for diabetic patients. However, anyone on diabetes medications should discuss peptide use with their prescribing physician. The lack of interaction in trials doesn’t guarantee safety in all individual cases, especially with injectable dosing.

Sources

  1. Heffernan M, Summers RJ, Thorburn A, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001;142(12):5182-5189. doi:10.1210/endo.142.12.8522

  2. Ioannides-Demos LL, Piccenna L, McNeil JJ. Pharmacotherapies for Obesity: Past, Current, and Future Therapies. Journal of Obesity. 2011;2011:179674. PMC3584306

  3. Stier H, Vos E, Kenley D. Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. Journal of Endocrinology and Metabolism. 2014;4(1-2):7-15. doi:10.14740/jem213w

  4. Ng FM, Sun J, Sharma L, et al. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Hormone Research. 2000;53(6):274-278. doi:10.1159/000053183

  5. FDA Briefing Document, Pharmacy Compounding Advisory Committee (PCAC) Meeting, December 4, 2024. AOD-9604-related bulk drug substances. fda.gov

  6. Thompson G. Obesity drug codenamed AOD9604 highly successful in trials. News-Medical. December 16, 2004. news-medical.net

  7. Holt Law. Deep Dive: Regulatory Status of Popular Compounded Peptides. djholtlaw.com

Get guides like this delivered weekly.

Evidence-based peptide research, protocol breakdowns, and provider reviews.

Get the Weekly Brief